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Abstract: There has been a rising interest in the possible association
between perioperative opioid use and postoperative outcomes in cancer
patients. Continuous surgical wound infiltration with local anesthetics is
a nonopioid analgesic technique that can be used as a postoperative pain
management alternative to opioid-based intravenous patient-controlled
analgesia (IV PCA). The aim of this study was to compare the effects of
an opioid-based analgesic regimen versus a local anesthetic wound
infiltration-based analgesic regimen on immune modulation and short-
term cancer recurrence or metastasis in patients undergoing laparo-
scopic resection of colorectal cancer.
Sixty patients undergoing laparoscopic resection of colorectal can-
cer were randomly assigned to either the opioid group or the ON-QJinae Lee, PhD, H h, MD,
n-Neyo Koo, MD, PhD
with an ON-Q pump and tramadol via IV PCA. Pethidine for the opioid
group and ketorolac or propacetamol for the ON-Q group were used as
rescue analgesics. Anesthesia was induced and maintained with pro-
pofol and remifentanil. The primary outcome was postoperative
immune function assessed by natural killer cell cytotoxicity (NKCC)
and interleukin-2. Secondary outcomes were postoperative compli-
cations, cancer recurrence, or metastasis within 1 year after surgery,
and postoperative inflammatory responses measured by white blood cell
count, neutrophil percentage, and C-reactive protein. Immune function
and inflammatory responses were measured before surgery and 24 and
48 hours after surgery.
Fifty-nine patients completed the study. In the circumstance of
similar pain control efficacy between the opioid group and the ON-Q
group, postoperative NKCC and interleukin-2 levels did not differ
between the 2 groups. The incidence of postoperative complications
and recurrence or metastasis within 1 year after surgery was comparable
between the groups. Postoperative inflammatory responses were also
similar between the groups.
When compared with ropivacaine wound infiltration-based analge-
sia, fentanyl-based analgesia did not further decrease NKCC or affect
short-term cancer recurrence or metastasis. Thus, a fentanyl-based
analgesic regimen and a ropivacaine wound infiltration-based analgesic
regimen can both be used for postoperative pain management in
laparoscopic resection of colorectal cancer.
(Medicine 95(19):e3602)
Abbreviations: ASA = American Society of Anesthesiologists,
BIS = bispectral index, CO2 = carbon dioxide, CRP = C-reactive
protein, E = effector cell, IL = interleukin, IQR = interquartile
range, IV PCA = intravenous patient-controlled analgesia, LDH =
lactate dehydrogenase, NK = natural killer, NKCC = NK cell
cytotoxicity, NRS = numerical rating scale, RPMI = roswell park
memorial institute, T = targeted cell, WBC = white blood cell.
INTRODUCTION
O pioids are a common first-choice analgesic for postopera-tive pain management. Opioid-based intravenous patient-
controlled analgesia (IV PCA) has been widely used for post-
operative analgesia due to its effectiveness and convenience
since the late 1960s1; however, there is an emerging interest in
the possible association between perioperative use of opioids
and recurrence or metastasis after cancer surgery.2–5 Immuno-
modulation by opioids occurs through direct action on immune
cells, modulation of the hypothalamic-pituitary-adrenal axis,
and modulation of sympathetic activity.6 However, the evi-ed immunomodulation is conflicting in
an studies. Fentanyl suppresses natural
n, which plays a major role in innate and
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adaptive immunity, and increases the risk of tumor metastasis
in a rat model.7,8 Fentanyl also suppresses postoperative NK cell
function in patients.9 However, fentanyl can improve NK
cell function, and low-dose remifentanil does not impair NK
cell function in healthy humans.10,11 Likewise, retrospective
results regarding the use of postoperative opioids and cancer
recurrence remain controversial. Postoperative opioid analgesia
was associated with increased risk of cancer recurrence after
radical prostatectomy when compared with epidural analgesia.2
On the contrary, there was no significant difference in overall or
disease-free survival between postoperative opioid analgesia
and epidural analgesia after laparoscopic resection of colorectal
cancer.3
Laparoscopic colorectal surgery has become popular for
the surgical treatment of colorectal cancer because there is
minimal surgical trauma, less postoperative pain, and a rapid
return to preoperative activity levels with a shorter hospital-
ization period.12 It also has shown beneficial outcomes in
terms of postoperative immune function, morbidity, cancer
recurrence, and cancer-related survival compared with open
surgery.13,14 Continuous wound infiltration with local anes-
thetics has been recognized as a useful nonopioid analgesic
technique for postoperative pain management after laparo-
scopic and open colorectal surgeries.15 Such nonopioid
analgesic techniques can be an alternative choice for cancer
patients undergoing surgery, since they can avoid the immu-
nosuppressive effects of opioids. However, no prospective
data are available regarding the effects of postoperative pain
management with opioids or with continuous wound infiltra-
tion on postoperative immune function.
The aims of this randomized study were to compare
postoperative immune function assessed by NK cell cytotox-
icity (NKCC) and interleukin (IL)-2, which is required for
proliferation and cytotoxic activities of NK cells; and to evalu-
ate short-term cancer recurrence or metastasis based on post-
operative pain management with opioids or with continuous
wound infiltration in patients undergoing laparoscopic resection
of colorectal cancer.
METHODS
This study was approved by the Severance Hospital Institu-
tional Review Board (protocol number: 4–2013–0044) and was
registered at http://clinicaltrials.gov (registration number
NCT02012244). Between January 2014 and December 2014,
we enrolled 60 patients aged 20 to 80 years with an American
Society of Anesthesiologists (ASA) physical status I to III who
underwent laparoscopic resection of colorectal cancer. These
patients were followed until 1 year after surgery. Written
informed consent was obtained from every patient. Patients
were not admitted to the study if they had drug allergies,
significant renal or hepatic impairment, high levels of C-reac-
tive protein (CRP), or leukocytosis (>11,000/mL) before
surgery.
Interventions
Patients were randomly assigned to one of the 2 groups
using a random number generator. The opioid group (n¼ 30)
received fentanyl via IV PCA. The ON-Q group (n¼ 30)
received continuous surgical wound infiltration of 0.5% ropi-
vacaine with an ON-Q pump. The ON-Q group also received IV
Kim et alPCAwith tramadol to match pain control efficacy between the 2
groups. The fentanyl PCA was composed of 2000mg fentanyl
(Hana Pharm, Seoul, Korea) and 0.3mg ramosetron (Nasea,
2 | www.md-journal.comAstellas, Tokyo, Japan) mixed with normal saline to a total
volume of 200mL. The tramadol PCAwas composed of 450mg
tramadol (Tridol, Yuhan Corp., Seoul, Korea) mixed with
normal saline to a total volume of 100mL. The bolus dose
was 1mL at a basal infusion rate of 1mL/h, with a lockout
interval of 7minutes in both groups. We used a PCA device
(Accumate 1100, WooYoung Medical, Seoul, Korea) in which
delivered amounts of the drug were automatically recorded
every 30minutes, and these data were transferred to a computer
for analysis. Continuous wound infiltration in the ON-Q group
was delivered by an elastomeric pump (ON-Q PainBuster, I-
Flow Corp., Lake Forest, CA) through 2 multiholed Soaker
catheters, each of which was located between subcutaneous fat
and fascia and below the fascia. The ON-Q was composed of
200mL 0.75% ropivacaine (Naropin, AstraZeneca, Seoul,
Korea) and 100mL normal saline, and was delivered at a flow
rate of 4mL/h (2mL/h per catheter).
Upon arrival in the operating room, electrocardiogram,
pulse oxygen saturation, invasive arterial pressure, and bispec-
tral index (BIS; A-2000 SP, Aspect Medical Systems, Norwood,
MA) were determined. Anesthesia was induced and maintained
with propofol (Fresofol, Fresenius Kabi Korea Ltd, Seoul,
Korea) and remifentanil (Ultiva, GlaxoSmithKline, Brentford,
UK) using a target-controlled infusion by a commercial total IV
anesthesia pump (Orchestra Base Primea, Fresenius-Vial,
Se´vres, France). The depth of anesthesia was maintained at a
BIS value of 40 to 60. Propofol and remifentanil were chosen as
anesthetic agents because neither impairs NK cell activity.11,16
Controlled ventilation was performed with an 8mL/kg tidal
volume and a positive end-expiratory pressure of 5 cm H2O, and
ventilator frequency was adjusted to maintain an end-tidal
carbon dioxide (CO2) between 35 and 40mm Hg. Pneumoper-
itoneum was induced by insufflation of CO2, and the intra-
abdominal pressure was maintained at 12 to 15mm Hg. At
10minutes before the end of surgery, 50mg fentanyl in the
opioid group and 50mg tramadol in the ON-Q group were
given, and 0.3mg ramosetron was given in both groups. In the
ON-Q group, a 5-mL bolus of 0.75% ropivacaine was injected
through each catheter of the ON-Q pump at the end of surgery.
IV PCA with fentanyl or tramadol was initiated at the end of
surgery and maintained during postoperative 48 hours in
each group.
Data Collection
The primary outcome of this study was postoperative
immune function assessed by NKCC and IL-2. Secondary
outcomes were postoperative complications and cancer recur-
rence or metastasis within 1 year after surgery, and post-
operative inflammatory responses measured by white blood
cell (WBC) count, neutrophil percentage, and CRP. Immune
function and inflammatory responses were measured
before the surgery, and 24 and 48 hours after surgery. Post-
operative complications were assessed by the Postoperative
Morbidity Survey, which is a reliable and valid survey of
postoperative morbidity in major elective surgery.17 Cancer
recurrence or metastasis was checked with a colonoscopy or
computed tomography.
Because of the possible impact of pain intensity on post-
operative immune function, we checked pain intensity using an
11-point numerical rating scale (NRS), from 0 to 10 (0¼ no pain
and 10¼worst pain) at rest and while coughing 1, 6, 12, 24, and
Medicine  Volume 95, Number 19, May 201648 hours postoperatively and controlled pain with a target of
resting NRS <4 using rescue analgesics (pethidine for the
opioids group and ketorolac or propacetamol for the ON-Q
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
group). In addition, the patients were advised to press the PCA
bolus button when NRS 4.
Assay for NKCC
Isolation of peripheral blood mononuclear cells and the
NKCC assay was performed as previously described.18 After
whole blood was mixed with the same volume of Roswell Park
Memorial Institute (RPMI) 1640 medium (Gibco, Invitrogen,
CO), it was laid on a Histipaque-1077 (Sigma, CA) and
centrifuged (2000 rpm for 20minutes at 108C). Then, a thin
layer of peripheral blood mononuclear cells was harvested and
washed twice with RPMI 1640 and resuspended in RPMI 1640
containing streptomycin.
NKCC was determined with the CytoTox 96 Non-Radio-
active Cytotoxicity Assay (Promega Co., WI) using K562 cells
as the target cell line. This colorimetric assay quantitatively
measures lactate dehydrogenase (LDH), a stable cytosolic
enzyme that is released upon cell lysis, in much the same
way that 51Cr is released in a radioactive assay. Briefly, per-
ipheral blood mononuclear cells (effector cell, E) and K562
cells (2 104 cells/well; targeted cell, T) were mixed in differ-
ent E:T ratios (10:1, 5:1, and 2.5:1) in a 96-well and incubated at
378C with 5% CO2 overnight according to the manufacturer’s
instructions.19 The NKCC of effector cells was measured with a
2030 multilabel reader (Victor X5, PerkinElmer) at 490 nm and
was calculated using the following equation:
Experimental Effector SpontaneousTarget Spontaneous
TargetMaximimTarget Spontaneous  100
‘‘Experimental’’ is the experimental LDH release of cocul-
tured effector and target cells, ‘‘effector spontaneous’’ and
‘‘target spontaneous’’ express the spontaneous released LDH
of the effector and target cells alone, respectively, and ‘‘target
maximum’’ is the maximum LDH release of target cells.
Interleukin-2 Assay
Interleukin-2 was measured in serum using a commercial
ELISA kit (Quantikine Human IL-2 ELISA kit; R&D System
Inc.) The absorbance was read at 450 nm using Spectra Max 190
micro-plate reader (Molecular Devices, Sunnyvale, CA).
Statistical Analysis
In previous studies that demonstrated the effect of fentanyl
and remifentanil on NKCC in normal volunteers, 7 and 10 subjects
were enrolled, respectively.10,11 About 30 subjects in each group
can reveal the different effects of drug therapy on NKCC.18
Therefore, we decided to include 30 patients in each group.
All data are presented as meanSD or median (inter-
quartile range [IQR]) for continuous variables or the number of
patients (percentage) for categorical variables. The Shapiro–
Wilk test and Q–Q plot were used to test continuous variables
for the normality assumption. Normally distributed variables
were analyzed with the independent t test, and non-normally
distributed variables were analyzed with the Mann–Whitney U
test. Categorical variables were evaluated with the chi-square
test or Fisher exact test, as appropriate. Variables measured over
time were analyzed with a linear mixed model, and the Mann–
Whitney U test and Wilcoxon signed-rank test were used to test
variables that did not meet normality. Adjustment for multiple
comparisons was performed with the Bonferroni correction
Medicine  Volume 95, Number 19, May 2016method. Two-sided P values of <0.05 were considered to
indicate statistical significance. Statistical analyses were per-
formed using SAS version 9.2 (SAS Inc., Cary, NC).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.RESULTS
Of the 69 patients assessed for eligibility, 60 patients were
enrolled and randomly assigned to the groups and 59 patients
(98 %) completed the study (Figure 1). One patient was
excluded from analysis due to conversion to open surgery.
There were no significant differences in the patient character-
istics including pathologic stage and operation details between
the 2 groups (Table 1). The total administered dose of fentanyl
was 994 296mg (meanSD) in the opioid group and the dose
of tramadol was 376 71mg (meanSD) in the ON-Q group
during the first 48 hours after surgery.
Postoperative Immune Function
As the 2 different pain management strategies showed
similar pain control efficacy (Figure 2), the possible impact of
different pain intensity between the 2 groups on postoperative
immune function can be ruled out. Postoperative immune
function assessed by NKCC and IL-2 were not different
between the 2 groups (Figure 3 and Table 2). NKCC tended
to decrease 24 hours after surgery and recover 48 hours after
surgery in both groups (Figure 3). Postoperative IL-2 levels
significantly increased in both groups compared with preopera-
tive values (Table 2). The difference between preoperative and
postoperative NKCC (NKCC 24 or 48 hours after surger-
yNKCC before surgery) and the difference between preo-
perative and postoperative IL-2 (IL-2 24 or 48 hours after
surgery IL-2 before surgery) were also similar between the
groups (data not shown).
Postoperative Outcomes
Postoperative hospital stay was 6 (5–8) days in the opioid
group and 6 (5–7) days in the ON-Q group (median [IQR],
P¼ 0.147). One patient in the opioid group was lost to follow-
up before 1 year after surgery. There was no patient mortality.
The incidence of postoperative complications and cancer recur-
rence or metastasis within 1 year after surgery was comparable
between the 2 groups. Three patients in the opioid group had
complications: postoperative anastomotic leakage 40 days after
surgery (colon and small bowel resection with end-to-end
anastomosis), intestinal obstruction 10 months after surgery
(conservative management), and intestinal obstruction 15 days
after surgery (conservative management). Three patients in the
ON-Q group had complications: septic shock during chemother-
apy 4 months after surgery (conservative management), acute
kidney injury 21 days after surgery (conservative management),
and intra-abdominal abscess 5 days after surgery (abscess
drainage with pig-tail catheter). One patient in the opioid group
had liver metastasis 3 months after surgery (wedge resection of
the liver), whereas 1 patient in the ON-Q group had lung
metastasis 9 months after surgery (chemotherapy).
Postoperative Inflammatory Responses
There was no difference in the postoperative inflammatory
responses assessed by WBC count, neutrophil percentage, and
CRP between the 2 groups (Table 3). In each group, post-
operative WBC count, neutrophil percentage, and CRP were
increased compared with preoperative values (Bonferroni-cor-
rected P< 0.001).
Postoperative Pain Management Methods and Immune FunctionDISCUSSION
The results of this prospective randomized trial suggest
that fentanyl IV PCA and the ropivacaine wound infiltration
www.md-journal.com | 3
TABLE 1. Patient Characteristics
Opioid (n¼ 30) ON-Q (n¼ 29) P
Age, years 66 9 63 11 0.27
Sex (male/female) 13/17 9/20 0.33
Body mass index, kg/m2 23.1 3.2 23.1 3.0 0.93
ASA physical status (I/II/III) 10/20/0 14/13/2 0.13
Operation details
Type of operation (AR/LAR/RHC/LHC) 11/10/6/3 12/8/4/5 0.77
Proximal resection margin, cm 12.3 3.7 10.5 4.1 0.08
Distal resection margin, cm 7.3 7.0 8.4 6.1 0.53
Duration of operation, minutes 148 (125–188) 164 (151–221) 0.14
Duration of pneumoperitoneum, minutes 110 (82–142) 116 (92–152) 0.39
Administered dose of propofol, mg 1312 (1140–1780) 1478 (1212–1740) 0.66
Administered dose of remifentanil, mg 1230 (995–1650) 1281 (973–1672) 0.94
Fluid intake, mL 1300 (1050–1990) 1400 (1200–1650) 0.59
Blood loss, mL 20 (10–50) 30 (20–50) 0.12
Pathologic stage
TNM stage (I/II/III) 14/6/10 8/8/13 0.32
T stage (1/2/3/4) 12/5/12/1 6/4/18/1 0.35
N stage (0/1/2) 20/8/2 16/9/4 0.56
Adjuvant chemotherapy 7 (23%) 13 (45%) 0.08
Adjuvant chemoradiotherapy 3 (10%) 1 (3%) 0.32
Values are meanSD, median (IQR) or number (proportion).
AR¼ anterior resection, ASA¼American Society of Anesthesiologists, LAR¼ low anterior resection, LHC¼ left hemicolectomy, RHC¼ right
hemicolectomy, TNM¼ tumor node metastasis.
n=64)
Lost to follow-up (n=0)
Allocated to the opioid group (n=30)
• Received allocated intervention (n=30)
Lost to follow-up (n=1)
• Conversion to open surgery (n=1)
Allocated to the ON-Q group (n=30)
• Received allocated intervention (n=30)
Assessed for eligibility ( 9)
Randomized (n=60)
Excluded (n=9)
• Not meeting inclusion criteria (n=8)
• Declined to participate (n=1)
Analysed (n=30) Analysed (n=29)
FIGURE 1. Patient assignment to study groups (randomized) and treatment protocols.
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scopic surgery for colorectal cancer from an immunological
standpoint. These 2 pain management methods were compar-
able in immunomodulation as assessed by NKCC and IL-2
levels, and showed no difference in short-term outcomes. In
addition, postoperative inflammatory responses were similar
between the 2 pain management methods.
Cancers including colorectal cancer have direct immuno-
suppressive effects on cell-mediated immunity.4,5,20 Even though
surgery is the mainstay for solid tumors, surgery itself can
promote the development of metastasis by releasing tumor cells
into circulation, suppressing the cellular immune system, and
augmenting angiogenesis.4,5 Therefore, antitumor immune
potential can have a significant impact onpostoperative outcomes
in cancer patients. Some experimental and retrospective clinical
evidence indicates an association between anesthetic and analge-
sic technique and cancer recurrence or metastasis, although
prospective, randomized clinical trials are scarce.2,15,17
Opioids can affect cell-mediated and humoral immunity by
acting directly on immune cells, the hypothalamic-pituitary-
adrenal axis, and sympathetic activity.6 However, the results of
opioid-induced immunomodulation are conflicting in exper-
imental and human studies. In a rat model of breast cancer
metastasis, low (100mg/kg) and high doses (300mg/kg) of
fentanyl administered 2 hours before, at the same time, or 1 hour
after tumor inoculation promoted lung tumor retention, which
was significantly correlated with the suppression of NKCC by
fentanyl.7 Administration of fentanyl (40mg/kg) 1 hour before
laparotomy was shown to suppress NKCC and significantly
increased the number of lung metastasis compared with cloni-
dine and ketamine in a rat model.8 Similarly, in a study with
patients undergoing abdominal surgery, half of them with
malignant disease and half of them with benign conditions,
high-dose fentanyl (75–100mg/kg) and lower-dose fentanyl (up
to 6mg/kg) during anesthesia had similar effects on the sup-
pression of NKCC 24 hours after abdominal surgery.9 This
suppression was more prolonged in patients who received a
high dose of fentanyl, in which NKCC suppression lasted until
48 hours after surgery. In contrast to the previous stated studies,
another study showed that clinically relevant doses of fentanyl
(initial does of 3mg/kg followed by a 2-hour infusion of 1.2mg/
kg/h) significantly increased NKCC at the end of infusion in
healthy participants.10 In our study, the mean administered dose
FIGURE 2. Numerical rating scale (NRS) for pain (A) at rest and (
expressed as meanSD. No difference between the groups.of fentanyl during the first 48 hours after surgery was 994mg
(minimum 549mg and maximum 2000mg), and rescue pethi-
dine (minimum 25mg and maximum 100mg) was allowed in
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.17 patients out of 30 patients in the opioid group. These doses of
opioids did not induce additional suppression of NKCC com-
pared with the local anesthetic wound infiltration technique
with IV tramadol.
NK cells participate in both innate and adaptive
immunity.21 They play an important role in immune surveil-
lance against local tumor growth and metastasis by direct
cellular cytotoxicity; thus lower NKCC is associated with
increased cancer metastasis.21,22 Antitumor responses in NKCC
are activated by various cytokines, such as IL-1, IL-2, IL-12, IL-
15, IL-18, IL-21, and type I interferons.21,22 As IL-2-activated
human NK cells can effectively kill colon carcinoma cells in
vitro,23 we investigated IL-2 for this study. NKCC was signifi-
cantly decreased and IL-2 was significantly increased after
surgery in both groups; however, there was no difference in
NKCC and IL-2 between the groups. These findings suggest
that the 2 pain management methods have similar immunomo-
dulatory effects in laparoscopic colorectal surgery.
There have been many studies on analgesia methods
(opioid analgesia or epidural analgesia) and cancer recurrence
and survival after surgery, most of which were retrospective
analyses.4,5 These results differ based on the type of surgery,
and even in colorectal cancer, the results are inconsistent.4,5 In a
retrospective analysis of open colorectal surgery, there was no
difference in cancer recurrence between opioid analgesia and
epidural analgesia, except for a potential benefit of epidural
analgesia in older patients.24,25 However, opioid analgesia was
associated with a higher mortality rate than epidural analge-
sia.25,26 In a prospective, randomized study with open colorectal
surgery, epidural analgesia was associated with improved sur-
vival among patients without preoperative metastasis for 1.46
years after surgery when compared with opioid analgesia,
though there was no beneficial effect on long-term survival.27
Although epidural analgesia has shown some favorable results
in open colorectal surgery, another retrospective study reported
that there was no difference between epidural analgesia and
opioid analgesia in overall survival or disease-free survival 5
years after laparoscopic colorectal cancer surgery.3 Therefore,
the survival advantage of epidural analgesia may be limited to
open colorectal cancer surgery since the immune response is
less affected by laparoscopic colorectal resection,13 which can
affect morbidity, cancer recurrence, and cancer-related survi-
val.14 However, no conclusions can be drawn regarding the
hile coughing 1, 6, 12, 24, and 48hours after surgery. Data areeffects of analgesia methods on cancer outcomes in laparo-
scopic colorectal surgery because no prospective results
are available.
www.md-journal.com | 5
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FIGURE 3. Changes in natural killer cell cytotoxicity after surgery.
Box plot indicates the median (solid line), interquartile range
(box), and values within 1.5 times the interquartile range (whis-
Kim et alkers). Outliers are indicated by circles. No difference between the
groups.

P<0.05 versus ‘‘before surgery’’ for each group (Bon-
ferroni-corrected). E¼ effector cell, T¼ target cell.Even though epidural analgesia is one of the key com-
ponents of enhanced recovery protocols in colorectal surgery,28
6 | www.md-journal.comthe benefit of epidural analgesia remains controversial in mini-
mally invasive laparoscopic colorectal surgery.29–31 Random-
ized clinical trials comparing epidural analgesia versus opioid-
based IV PCA in laparoscopic colorectal surgery have produced
favorable results for opioid-based IV PCA, showing a faster
returnof bowel function, fewer overall complications, and shorter
hospital stays in patients with IV PCA.30,31 Patients with epidural
analgesia needed more perioperative vasopressor treatment with
no difference in postoperative pain scores compared with IV
PCA.31 Therefore, opioid-based IV PCA may be more appro-
priate than epidural analgesia in laparoscopic colorectal surgery.
Continuous surgical wound infiltration with local anes-
thetics can be used as a postoperative pain management alterna-
tive to opioid-based IV PCA after laparoscopic colorectal
surgery.15 In our study, the ON-Q systemwith 0.5% ropivacaine
combined with IV tramadol was chosen as an alternative pain
management method to the traditional opioid analgesia. Many
in vitro studies have reported antiproliferative or cytotoxic
effects of local anesthetics on tumor cells.4,5 Ropivacaine
reduced in vitro proliferation of mesenchymal stem cells, which
are key players in tumor growth, and increased cytotoxicity in a
concentration-dependent manner while inhibiting transcription
pathways related to neoplasia and metastasis.32 Similarly, all
local anesthetics including ropivacaine induced concentration-
dependent apoptosis and necrosis in T-lymphoma cells in
vitro.33 Tramadol, which inhibits the reuptake of serotonin
and norepinephrine in addition to binding with low affinity
to m-opioid receptors, can stimulate NK cell activity in both rats
and humans.34,35 In a rat model, the administration of tramadol
(20 and 40mg/kg) before and after laparotomy significantly
prevented surgery-induced suppression of NKCC and blocked
the enhancement of lung metastasis induced by surgery. In
contrast, the administration of 10mg/kg of morphine did not
prevent surgery-induced immunosuppression and was not able
to modify the enhancement of lung metastasis after surgery.34
These different immunomodulatory effects of morphine and
tramadol can also be found in human studies. In 1 study, patients
received either 100mg tramadol or 10mg morphine immedi-
ately after abdominal surgery for uterine carcinoma. NKCC
significantly increased in patients treated with tramadol, though
there was no significant change of NKCC in patients with
morphine.35 Considering the favorable impact of tramadol on
cellular immunity, tramadol may be a good alternative analgesic
to opioids in cancer patients. Contrary to our expectation that
ropivacaine wound infiltration with IV tramadol is more
beneficial for immune function than opioid analgesia, post-
operative NKCC and 1 year cancer recurrence or metastasis
were similar between the 2 groups. This may be because this
study was performed in patients who received laparoscopic
surgery, which induces less immunosuppression than open
surgery.13
There are some limitations to this study. First, we only
measured NKCC during the first 48 hours after surgery and
followed up on patients for cancer recurrence or metastasis for 1
year after surgery. In laparoscopic colorectal surgery, IV PCA is
usually stopped within 2 days after surgery,30 and our center
also uses IV PCA for 2 days after surgery. Therefore, we
checked NKCC only for 48 hours postoperatively, during which
2 pain management methods were applied. Even though the 1-
year rates of cancer recurrence or metastasis were similar
between the 2 groups, further studies that evaluate long-term
Medicine  Volume 95, Number 19, May 2016outcomes are needed. Second, we cannot exclude the possibility
of immunosuppression by higher doses of fentanyl than used in
this study, as the mean administered dose of fentanyl during the
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Changes in Interleukin-2 Levels After Surgery
Opioid (n¼ 30) ON-Q (n¼ 29) P
Interleukin-2, pg/mL Before surgery 1.64 (0.85–3.14) 2.09 (0.95–2.89) >0.99
24 hours after surgery 3.01 (1.92–4.36)

2.95 (2.19–3.89)

>0.99
48 hours after surgery 2.84 (1.55–3.95) 2.87 (2.26–4.02)

>0.99
Values are median (IQR).
P value is a Bonferroni-corrected value.
P< 0.05 versus ‘‘before surgery’’ for each group (Bonferroni-corrected).
TABLE 3. Changes in White Blood Cell Count, Neutrophil Percentage and C-reactive Protein After Surgery
Opioid (n¼ 30) ON-Q (n¼ 29) P
WBC count, /mL Before surgery 6439 1657 6659 1706 >0.99
24 hours after surgery 8681 2601 8571 2154 >0.99
48 hours after surgery 8180 2265 8667 1764 >0.99
Neutrophil percentage, % Before surgery 60.9 9.5 57.0 10.9 0.64
24 hours after surgery 77.4 6.1 78.1 7.6 >0.99
48 hours after surgery 75.4 7.3 75.7 7.9 >0.99
CRP, mg/L Before surgery 1.1 (0.9–2.0) 1.5 (1.0–5.1) >0.99
24 hours after surgery 43.7 (30.1–69.6)

39.9 (30.2–62.5)

>0.99
48 hours after surgery 67.4 (44.5–111.8)

91.0 (66.7–101.5)

>0.99
Values are meanSD or median (IQR).
P value is a Bonferroni corrected value.
rect
Medicine  Volume 95, Number 19, May 2016 Postoperative Pain Management Methods and Immune Functionfirst 48 hours after surgery was 994mg, with a maximum dose of
2000mg in the opioid group. However, as the patient self-
administered fentanyl via the PCA bolus button, there may
be no need for higher doses of fentanyl than used in this study
for laparoscopic colorectal surgery. In addition, Spearman
correlation analysis showed no correlation between the admi-
nistered dose of fentanyl and postoperative NKCC within the
range of fentanyl used in this study. Lastly, we assessed only
NK cells as a surrogate marker for immune function, although
T-helper cells and cytotoxic T cells are also antitumor effector
cells. We chose NK cells since they are involved in both innate
and adaptive immunity, unlike T cells, which mediate only
adaptive immunity.21 Furthermore, NK cells are an emerging
target for immunotherapy in cancer patients because of their
vital role in immune defense against cancer.22,23
In conclusion, fentanyl-based analgesia and ropivacaine
wound infiltration-based analgesia have similar immunomodu-
latory effects after laparoscopic resection of colorectal cancer.
As there was no difference in cancer recurrence or metastasis
during 1 year after surgery, there is no need to refrain from
opioid use as perioperative pain management in laparoscopic
colorectal surgery. The ropivacaine wound infiltration tech-
nique with additional IV tramadol can be considered as an
alternative pain management to opioid-based IV PCA in
laparoscopic surgery.
ACKNOWLEDGMENTS
CRP¼C-reactive protein, WBC¼white blood cell.
P< 0.001 versus ‘‘before surgery’’ for each group (Bonferroni-corThe authors thank Dong-Su Jang, MFA, medical illus-
trator, Medical Research Support Section, Yonsei University
College of Medicine, for his help with the figures.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.REFERENCES
1. Grass JA. Patient-controlled analgesia. Anesth Analg. 2005;101(5 Suppl):
S44–S61.
2. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for
radical prostatectomy surgery affects cancer recurrence: a retro-
spective analysis. Anesthesiology. 2008;109:180–187.
3. Day A, Smith R, Jourdan I, et al. Retrospective analysis of the
effect of postoperative analgesia on survival in patients after
laparoscopic resection of colorectal cancer. Br J Anaesth. 2012;109:
185–190.
4. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques
affect cancer recurrence or metastasis? Br J Anaesth. 2012;109
(Suppl 1:):i17–i28.
5. Snyder GL, Greenberg S. Effect of anaesthetic technique and other
perioperative factors on cancer recurrence. Br J Anaesth. 2010;105:
106–115.
6. Al-Hashimi M, Scott SW, Thompson JP, et al. Opioids and immune
modulation: more questions than answers. Br J Anaesth. 2013;111:
80–88.
7. Shavit Y, Ben-Eliyahu S, Zeidel A, et al. Effects of fentanyl on
natural killer cell activity and on resistance to tumor metastasis in
rats. Dose and timing study. Neuroimmunomodulation. 2004;11:
255–260.
8. Forget P, Collet V, Lavand’homme P, et al. Does analgesia and
condition influence immunity after surgery? Effects of fentanyl,
ketamine and clonidine on natural killer activity at different ages.
Eur J Anaesthesiol. 2010;27:233–240.
ed).9. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large
versus small doses of fentanyl on natural killer cell cytotoxicity in
the perioperative period. Anesth Analg. 1996;82:492–497.
www.md-journal.com | 7
10. Yeager MP, Procopio MA, DeLeo JA, et al. Intravenous fentanyl
increases natural killer cell cytotoxicity and circulating CD16 (þ)
lymphocytes in humans. Anesth Analg. 2002;94:94–99.
11. Cronin AJ, Aucutt-Walter NM, Budinetz T, et al. Low-dose
remifentanil infusion does not impair natural killer cell function in
healthy volunteers. Br J Anaesth. 2003;91:805–809.
12. Jones OM, Lindsey I, Cunningham C. Laparoscopic colorectal
surgery. BMJ. 2011;343:d8029.
13. Wichmann MW, Huttl TP, Winter H, et al. Immunological effects of
laparoscopic vs open colorectal surgery: a prospective clinical study.
Arch Surg. 2005;140:692–697.
14. Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-
assisted colectomy versus open colectomy for treatment of non-
metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–
2229.
15. Ventham NT, O’Neill S, Johns N, et al. Evaluation of novel local
anesthetic wound infiltration techniques for postoperative pain
following colorectal resection surgery: a meta-analysis. Dis Colon
Rectum. 2014;57:237–250.
16. Melamed R, Bar-Yosef S, Shakhar G, et al. Suppression of natural
killer cell activity and promotion of tumor metastasis by ketamine,
thiopental, and halothane, but not by propofol: mediating mechan-
isms and prophylactic measures. Anesth Analg. 2003;97:1331–1339.
17. Grocott MP, Browne JP, Van der Meulen J, et al. The Postoperative
Morbidity Survey was validated and used to describe morbidity after
major surgery. J Clin Epidemiol. 2007;60:919–928.
18. Kwak JH, Baek SH, Woo Y, et al. Beneficial immunostimulatory
effect of short-term Chlorella supplementation: enhancement of
natural killer cell activity and early inflammatory response (rando-
mized, double-blinded, placebo-controlled trial) Nutr J. 2012;11:53.
19. Pries R, Wulff S, Kesselring R, et al. Up-regulation of NK cell
function against head and neck cancer in response to ss-isRNA
requires TLR7. Int J Oncol. 2008;33:993–1000.
20. Evans C, Dalgleish AG, Kumar D. Review article: immune
suppression and colorectal cancer. Aliment Pharmacol Ther.
2006;24:1163–1177.
21. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity?
The example of natural killer cells. Science. 2011;331:44–49.
22. Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer.
J Immunol. 2007;178:4011–4016.
Kim et alnoma cells is mediated by natural cytotoxicity receptors (NCRs) and
stimulated by parvovirus infection of target cells. BMC Cancer.
2013;13:367.
8 | www.md-journal.com24. Gottschalk A, Ford JG, Regelin CC, et al. Association between
epidural analgesia and cancer recurrence after colorectal cancer
surgery. Anesthesiology. 2010;113:27–34.
25. Cummings KC 3rd, Xu F, et al. A comparison of epidural analgesia
and traditional pain management effects on survival and cancer
recurrence after colectomy: a population-based study. Anesthesiol-
ogy. 2012;116:797–806.
26. Gupta A, Bjornsson A, Fredriksson M, et al. Reduction in mortality
after epidural anaesthesia and analgesia in patients undergoing rectal
but not colonic cancer surgery: a retrospective analysis of data from
655 patients in central Sweden. Br J Anaesth. 2011;107:164–170.
27. Christopherson R, James KE, Tableman M, et al. Long-term survival
after colon cancer surgery: a variation associated with choice of
anesthesia. Anesth Analg. 2008;107:325–332.
28. Lassen K, Soop M, Nygren J, et al. Consensus review of optimal
perioperative care in colorectal surgery: Enhanced Recovery After
Surgery (ERAS) Group recommendations. Arch Surg. 2009;144:961–
969.
29. Levy BF, Tilney HS, Dowson HM, et al. A systematic review of
postoperative analgesia following laparoscopic colorectal surgery.
Colorectal Dis. 2010;12:5–15.
30. Levy BF, Scott MJ, Fawcett W, et al. Randomized clinical trial of
epidural, spinal or patient-controlled analgesia for patients under-
going laparoscopic colorectal surgery. Br J Surg. 2011;98:1068–
1078.
31. Hubner M, Blanc C, Roulin D, et al. Randomized clinical trial on
epidural versus patient-controlled analgesia for laparoscopic color-
ectal surgery within an enhanced recovery pathway. Ann Surg.
2015;261:648–653.
32. Lucchinetti E, Awad AE, Rahman M, et al. Antiproliferative effects
of local anesthetics on mesenchymal stem cells: potential implica-
tions for tumor spreading and wound healing. Anesthesiology.
2012;116:841–856.
33. Werdehausen R, Braun S, Fazeli S, et al. Lipophilicity but not
stereospecificity is a major determinant of local anaesthetic-induced
cytotoxicity in human T-lymphoma cells. Eur J Anaesthesiol.
2012;29:35–41.
34. Gaspani L, Bianchi M, Limiroli E, et al. The analgesic drug
tramadol prevents the effect of surgery on natural killer cell activity
and metastatic colonization in rats. J Neuroimmunol. 2002;129:
18–24.
Medicine  Volume 95, Number 19, May 201635. Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol
23. Bhat R, Rommelaere J. NK-cell-dependent killing of colon carci-and morphine on immune responses and pain after surgery in cancer
patients. Anesth Analg. 2000;90:1411–1414.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
